Lauri Moilanen

Lauri Moilanen

Auto-generated profile, based on publicly available information

Lauri Moilanen

Department of Pathology, Hospital Nova of Central Finland, Jyväskylä, Finland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
IMIlari Mäki-Opas
Ilari Mäki-Opas
MHMari Hämäläinen
Mari Hämäläinen
LMLauri J. Moilanen
Lauri J. Moilanen
HSHeini Sood
Heini Sood
TLTiina Leppänen
Tiina Leppänen
EMEeva Moilanen
Eeva Moilanen

12 November 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Lynch syndrome is characterized by the development of microsatellite-instable cancers that share neoantigens, offering an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine in clinical development, employing viral vectors encoding 209 shared neoantigen peptides derived from frameshift mutations (FSM) commonly found in microsatellite-instable tumors. In this study, we investigated the presence and dynamics of NOUS-209 targeted FSMs in both primary and metachronous Lynch syndrome–associated cancers. Whole-exome sequencing was performed for 73 tumors, including 58 colorectal cancers and 15 urothelial cancers, from 58 individuals with confirmed Lynch syndrome. A median of 57 FSMs per colorectal cancer and 24 FSMs per urothelial cancer were observed, with similar FSM burdens in both primary and metachronous tumors. Analysis of nine matched primary–metachronous tumor pairs revealed evidence of immune editing: FSMs predicted to encode highly immunogenic neoepitopes were selectively lost in metachronous tumors, whereas those with lower predicted immunogenicity were retained. Importantly, all subsequent primary cancers acquired novel FSMs encoding neoantigens with strong predicted HLA-binding affinity, supporting the rationale for NOUS-209–mediated immune interception. These findings demonstrated that NOUS-209 FSMs are present in both colorectal cancers and urothelial cancers in Lynch syndrome, expanding the therapeutic potential of NOUS-209 beyond colorectal cancer. Moreover, the emergence of novel targetable FSMs in metachronous tumors suggests that NOUS-209 immunotherapy may be effective in the prevention of both primary and metachronous Lynch syndrome–associated cancers.

2 April 2026
Verified
Other
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Clinical characteristics of the colorectal cancer and urothelial cancer cohorts.

2 April 2026
Verified
Other
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Supplementary Figure S4 shows the immune-driven evolution of tumor FSP profiles in Lynch syndrome–associated cancers, highlighting FSPs that are lost, maintained, or newly gained under T cell surveillance.

2 April 2026
Verified
Other
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Supplementary Figure S3 shows correlations between CD8+ T cell infiltration (in tumor core and invasive margin) and both tumor mutational burden and NOUS-209 FSMs

2 April 2026
Verified
Other
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Supplementary Figure S5 shows the number and distribution of predicted MHC-II binders among lost, kept, and gained NOUS-209–derived epitopes across patients.